Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage

Phase 2

Completed

Conditions: Acquired Bleeding Disorder
Intracerebral Haemorrhage

Interventions: Drug: placebo
Drug: activated recombinant human factor VII

First Posted Date: 2012-03-27

Last Posted Date: 2017-01-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 40

Registration Number: NCT01563445

Locations: 🇺🇸
Novo Nordisk Investigational Site, New York, New York, United States

Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A
Haemophilia B

Interventions: Drug: activated recombinant human factor VII

First Posted Date: 2012-03-26

Last Posted Date: 2017-01-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 18

Registration Number: NCT01562587

Locations: 🇬🇧
Novo Nordisk Investigational Site, Oxford, United Kingdom

Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: repaglinide
Drug: insulin NPH

First Posted Date: 2012-03-26

Last Posted Date: 2017-02-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 213

Registration Number: NCT01562561

Locations: 🇨🇳
Novo Nordisk Investigational Site, Tainan city, Taiwan

Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients

Phase 4

Completed

Conditions: Growth Hormone Disorder
Adult Growth Hormone Deficiency

Interventions: Drug: placebo
Drug: somatropin

First Posted Date: 2012-03-26

Last Posted Date: 2024-02-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 22

Registration Number: NCT01562834

Locations: 🇫🇷
Novo Nordisk Investigational Site, Vandoeuvre Les Nancy, France

Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease

Phase 3

Completed

Conditions: Acquired Bleeding Disorder
Cardiac Surgery Requiring Cardiopulmonary Bypass

Interventions: Drug: placebo
Drug: activated recombinant human factor VII

First Posted Date: 2012-03-26

Last Posted Date: 2017-01-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 82

Registration Number: NCT01562574

Locations: 🇦🇺
Novo Nordisk Investigational Site, Parkville, Australia

Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy

Phase 2

Completed

Conditions: Acquired Bleeding Disorder
Cirrhosis

Interventions: Drug: activated recombinant human factor VII
Drug: placebo

First Posted Date: 2012-03-26

Last Posted Date: 2017-01-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 235

Registration Number: NCT01562821

Locations: 🇹🇭
Novo Nordisk Investigational Site, Bangkok, Thailand

Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A With Inhibitors
Acquired Bleeding Disorder
Acquired Haemophilia
Glanzmann's Disease
Healthy
Congenital FVII Deficiency
Haemophilia B With Inhibitors

Interventions: Drug: activated recombinant human factor VII

First Posted Date: 2012-03-23

Last Posted Date: 2017-01-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 28

Registration Number: NCT01561417

Locations: 🇫🇷
Novo Nordisk Investigational Site, Paris, France

Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis

Phase 2

Completed

Conditions: Other Haemostasis Disorder
Haemorrhagic Cystitis

Interventions: Drug: activated recombinant human factor VII

First Posted Date: 2012-03-23

Last Posted Date: 2017-01-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 7

Registration Number: NCT01561352

Locations: 🇺🇸
Novo Nordisk Investigational Site, Houston, Texas, United States

Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A With Inhibitors
Haemophilia B With Inhibitors

Interventions: Drug: eptacog alfa (activated)

First Posted Date: 2012-03-23

Last Posted Date: 2016-11-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 17

Registration Number: NCT01561924

Locations: 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom

Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State

Phase 1

Completed

Conditions: Haemophilia A
Haemophilia B
Congenital Bleeding Disorder

Interventions: Drug: activated recombinant human factor VII

First Posted Date: 2012-03-23

Last Posted Date: 2016-05-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 30

Registration Number: NCT01562457

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy